Improved outcomes of kidney-after-liver transplantation after the implementation of the safety net policy.
Journal
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
ISSN: 1527-6473
Titre abrégé: Liver Transpl
Pays: United States
ID NLM: 100909185
Informations de publication
Date de publication:
29 Nov 2023
29 Nov 2023
Historique:
received:
15
08
2023
accepted:
10
11
2023
medline:
28
11
2023
pubmed:
28
11
2023
entrez:
28
11
2023
Statut:
aheadofprint
Résumé
The number of kidney after liver transplants (KALT) increased after the implementation of the UNOS safety net policy but the effects of the policy on KALT outcomes remain unknown. Using the UNOS database, we identified KALT between 60 and 365 days from liver transplant (LT) from 1/1/2010 to 12/31/2020. The main outcome was 1- and 3-year patient, liver and kidney graft survival. Secondary outcomes inlcuded 6-month and 1-year acute rejection (AR) of liver and kidney, and 1-year kidney allograft function. Of the 256 KALT, 90 were pre-policy and 166 post-policy. Compared to pre-policy, post-policy 1- and 3-year liver graft survival was higher (54% and 54% vs. 86% and 81% respectively, p<0.001) while 1- and 3-year kidney graft survival (99% and 75% vs. 92% and 79% respectively, p=0.19), and 1- and 3-year patient survival (99% and 99% vs. 95% and 89% respectively, p=0.11) were not significantly different. Subgroup analysis revealed similar trends in patients with and without renal failure at LT. Liver AR at 6 months was lower post-policy (6.3% vs. 18.3%, p=0.006) but was similar (10.5% vs. 13%, p=0.63) at 1-year. Kidney AR was unchanged post-policy at 6 months and 1-year. Creatinine at 1-year did not differ post- versus pre-policy (1.4 mg/dL vs. 1.3 mg/dL, p=0.07) despite higher proportion of deceased donor, higher kidney donor profile index (KDPI), and longer kidney cold ischemia time post-policy (p<0.05 for all). This 3-year follow-up after the 2017 UNOS policy revision demonstrated that the safety net implementation has resulted in improved liver outcomes for KALT patients with no increased AR of the liver or the kidney allografts.
Sections du résumé
BACKGROUND
BACKGROUND
The number of kidney after liver transplants (KALT) increased after the implementation of the UNOS safety net policy but the effects of the policy on KALT outcomes remain unknown.
METHODS
METHODS
Using the UNOS database, we identified KALT between 60 and 365 days from liver transplant (LT) from 1/1/2010 to 12/31/2020. The main outcome was 1- and 3-year patient, liver and kidney graft survival. Secondary outcomes inlcuded 6-month and 1-year acute rejection (AR) of liver and kidney, and 1-year kidney allograft function.
RESULTS
RESULTS
Of the 256 KALT, 90 were pre-policy and 166 post-policy. Compared to pre-policy, post-policy 1- and 3-year liver graft survival was higher (54% and 54% vs. 86% and 81% respectively, p<0.001) while 1- and 3-year kidney graft survival (99% and 75% vs. 92% and 79% respectively, p=0.19), and 1- and 3-year patient survival (99% and 99% vs. 95% and 89% respectively, p=0.11) were not significantly different. Subgroup analysis revealed similar trends in patients with and without renal failure at LT. Liver AR at 6 months was lower post-policy (6.3% vs. 18.3%, p=0.006) but was similar (10.5% vs. 13%, p=0.63) at 1-year. Kidney AR was unchanged post-policy at 6 months and 1-year. Creatinine at 1-year did not differ post- versus pre-policy (1.4 mg/dL vs. 1.3 mg/dL, p=0.07) despite higher proportion of deceased donor, higher kidney donor profile index (KDPI), and longer kidney cold ischemia time post-policy (p<0.05 for all).
CONCLUSIONS
CONCLUSIONS
This 3-year follow-up after the 2017 UNOS policy revision demonstrated that the safety net implementation has resulted in improved liver outcomes for KALT patients with no increased AR of the liver or the kidney allografts.
Identifiants
pubmed: 38015446
doi: 10.1097/LVT.0000000000000302
pii: 01445473-990000000-00292
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 American Association for the Study of Liver Diseases.